Last updated: 18 April 2018 at 7:36am EST

Curt A. Iii Herberts Net Worth




The estimated Net Worth of Curt A. Iii Herberts is at least $956 Thousand dollars as of 13 April 2018. Curt Herberts owns over 8,163 units of Sangamo Therapeutics Inc stock worth over $19,142 and over the last 8 years Curt sold SGMO stock worth over $936,907.

Curt Herberts SGMO stock SEC Form 4 insiders trading

Curt has made over 13 trades of the Sangamo Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Curt exercised 8,163 units of SGMO stock worth $114,853 on 13 April 2018.

The largest trade Curt's ever made was selling 16,630 units of Sangamo Therapeutics Inc stock on 30 November 2017 worth over $268,242. On average, Curt trades about 8,529 units every 20 days since 2016. As of 13 April 2018 Curt still owns at least 22,788 units of Sangamo Therapeutics Inc stock.

You can see the complete history of Curt Herberts stock trades at the bottom of the page.



What's Curt Herberts's mailing address?

Curt's mailing address filed with the SEC is 501 Canal Blvd, Richmond, CA 94804, USA.

Insiders trading at Sangamo Therapeutics Inc

Over the last 24 years, insiders at Sangamo Therapeutics Inc have traded over $87,969,621 worth of Sangamo Therapeutics Inc stock and bought 3,434,008 units worth $48,483,268 . The most active insiders traders include Capital Management, L.P.Ra ..., Le Roy C Kopp, and Inc.Biogen Ma Inc. Biogen. On average, Sangamo Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $40,671. The most recent stock trade was executed by Inc.Biogen Ma Inc. Biogen on 26 September 2023, trading 6,000,000 units of SGMO stock currently worth $3,000,000.



What does Sangamo Therapeutics Inc do?

for sangamo therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. our scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. currently we are conducting clinical trials, including the first ever in vivo human genome editing studies. to learn more about sangamo, visit the our website at www.sangamo.com.



What does Sangamo Therapeutics Inc's logo look like?

Sangamo Therapeutics Inc logo

Complete history of Curt Herberts stock trades at Sangamo Therapeutics Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
13 Apr 2018 Curt A. Iii Herberts
Sr.VP and Chief Business Officer
Option 8,163 $14.07 $114,853
13 Apr 2018
22,788
2 Apr 2018 Curt A. Iii Herberts
Sr.VP and Chief Business Officer
Option 2,278 $5.35 $12,187
2 Apr 2018
16,903
1 Mar 2018 Curt A. Iii Herberts
Sr.VP and Chief Business Officer
Option 15,000 $9.86 $147,900
1 Mar 2018
29,625
1 Feb 2018 Curt A. Iii Herberts
Sr.VP and Chief Business Officer
Option 15,000 $3.50 $52,500
1 Feb 2018
29,625
2 Jan 2018 Curt A. Iii Herberts
Sr.VP and Chief Business Officer
Sale 15,000 $17.26 $258,900
2 Jan 2018
6,250
4 Dec 2017 Curt A. Iii Herberts
Sr.VP and Chief Business Officer
Option 11,803 $12.12 $143,052
4 Dec 2017
27,636
30 Nov 2017 Curt A. Iii Herberts
Sr.VP and Chief Business Officer
Sale 16,630 $16.13 $268,242
30 Nov 2017
15,833
2 Oct 2017 Curt A. Iii Herberts
Sr.VP and Chief Business Officer
Option 15,000 $7.66 $114,900
2 Oct 2017
19,587
1 Sep 2017 Curt A. Iii Herberts
Sr.VP and Chief Business Officer
Sale 15,000 $15.00 $225,000
1 Sep 2017
15,833
11 Aug 2017 Curt A. Iii Herberts
Sr.VP and Chief Business Officer
Option 11,474 $4.11 $47,158
11 Aug 2017
25,517
14 Jul 2017 Curt A. Iii Herberts
Sr.VP and Chief Business Officer
Sale 15,000 $10.00 $150,000
14 Jul 2017
20,517
1 Jun 2017 Curt A. Iii Herberts
Sr.VP and Chief Business Officer
Sale 2,000 $6.80 $13,600
1 Jun 2017
35,345
11 May 2017 Curt A. Iii Herberts
Sr.VP and Chief Business Officer
Sale 2,639 $8.02 $21,165
11 May 2017
37,345


Sangamo Therapeutics Inc executives and stock owners

Sangamo Therapeutics Inc executives and other stock owners filed with the SEC include: